Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases

Clinical Genitourinary Cancer

Volumn 5, Issue 6, 2007, Pages 390-396

  Saad, Fred ^a   Chen, Yin Miao ^b   Gleason, Donald M ^c   Chin, Joseph ^d  

^a NOTRE DAME HOSPITAL   (Canada)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Advanced Clinical Therapeutics   (United States)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Bisphosphonates; Bone health; Skeletal morbidity; Skeletal related events

Indexed keywords

CALCIUM; PLACEBO; VITAMIN D; ZOLEDRONIC ACID;

ADULT; ANEMIA; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER RISK; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NAUSEA; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

EID: 35348826314     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2007.n.022     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-130.
2. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005; 16:579-584.
3. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96:879-882.
4. LoRusso P. Analysis of skeletal-related events in breast cancer and response to therapy. Semin Oncol 2001; 28(suppl):22-27.
5. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with Pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98:1735-1744.
6. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of Pamidronate in reducing skeletal events in patients with advanced multiple myeloma. For the Myeloma Aredia Study Group. N Engl J Med 1996; 334:488-493.
7. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16:2038-2044.
8. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88:1082-1090.
9. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, compararive ttial. Cancer J 2001; 7:377-387.
10. Saad F. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 2002; 1:145-152.
11. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
12. Kaminski M, Rosen L, Gordon D, et al. Zoledronic acid versus pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications. Proc Am Soc Clin Oncol 2004; 23:90 (Abstract #857).
13. Major PP, Cook RJ, Chen BL, et al. Survival-adjusted multiple event analysis of skeletal complications from bone metastases: a comprehensive analysis of treatment benefit. Presented at: 4th International Conference on Cancer-Induced Bone Diseases; December 7-9, 2003. San Antonio, TX. Abstract #84.
14. Major PP, Cook RJ, Chen B-L, et al. Survival-adjusted cumulative event analysis of skeletal-related events in patients with cancer metastatic to bone in trials of zoledronic acid. Presented at: What Is New in Bisphosphonates? Seventh Workshop on Bisphosphonates - From the Laboratory to the Patient; March 24-26, 2004; Davos, Switzerland. Poster #71.
15. Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 2005; 23:8219-8224.
16. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample srudy. Ann Stat 1982; 10:1100-1120.
17. Saad F, Sternberg CN. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy. Nat Clin Pract Urol 2007; 4(suppl 1):S3-S13.
18. Conte PF, Rosen LS, Gordon D, et al. Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma: analysis of patients at high risk for skeletal complications. Presented at: 29th European Society for Medical Oncology Congress; October 29-November 2, 2004; Vienna, Austria. Abstract #463PD.
19. Hirsh V, Tchekmedyian NS, Rosen LS, et al. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 2004; 6:170-174.
20. Major PP, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 2002; 25(suppl):S10-S18.
21. Major PP, Cook RJ, Chen B, et al. Multiple event analysis of zoledronic acid trials in patients with cancer metastatic to bone. Proc Am Soc Clin Oncol 2003; 22(suppl):762 (Abstract #3062).